Energy Expenditure of People Living With HIV/AIDS

Overview

Background: Several studies have reported increased resting energy expenditure (REE) in people living with HIV/AIDS possibly due to changes in body composition that occurs in HIV lipodystrophy syndrome. The aim of this study was to evaluate the influence of the use of lipid-lowering drugs in resting energy expenditure (REE) and total energy expenditure (TEE) in patients seropositive for HIV in treatment of lipodystrophy.

Full Title of Study: “Influence of Lipid-lowering Drugs in Patients Seropositive for HIV With Lipodystrophy in Resting Energy Expenditure and Total Energy Expenditure”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: June 2014

Detailed Description

REE was measured by indirect calorimetry. TEE was measured by doubly labeled water (DLW) technique and an activity monitor based on accelerometry (AM).

Interventions

  • Drug: use of lipid-lowering drugs.
    • The patients shoud be in use of a lipid-lowering drugs previouly, at least one month before of the begining of the study.

Arms, Groups and Cohorts

  • LIPO-HIPO-
    • HIV-seropositive without lipodystrophy and no use of lipid-lowering drugs.
  • LIPO+HIPO-
    • HIV-seropositive with lipodystrophy and no use of lipid-lowering drugs.
  • LIPO+HIPO+
    • HIV-seropositive with lipodystrophy and use of lipid-lowering drugs.

Clinical Trial Outcome Measures

Primary Measures

  • Total Energy Expenditure (kcal/d)
    • Time Frame: 14 day
  • Resting Energy Expenditure (kcal/d)
    • Time Frame: 1 day

Secondary Measures

  • Correlation between doubly labeled water and accelerometer to measure total energy expenditure (ICC, 95% CI)
    • Time Frame: 14 days

Participating in This Clinical Trial

Inclusion Criteria

  • Use of antiretroviral therapy for at least 4 months – A cluster of differentiation 4 (CD4) T-cell count of >200 cells/mm3 – Use of lipid-lowering drugs for at least 1 month (group HIV-seropositive with lipodystrophy and use of lipid-lowering) Exclusion Criteria:

  • Signs or symptoms of opportunistic infections – Thyroid disease

Gender Eligibility: Male

Minimum Age: 18 Years

Maximum Age: 60 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Sao Paulo General Hospital
  • Collaborator
    • Fundação de Amparo à Pesquisa do Estado de São Paulo
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.